Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant XELOX/AVASTIN for Nonresectable Colorectal Liver Metastases
NCT00408772Phase 2Withdrawn
- Sponsor
- University of California, Davis
- Start
- Jun 2007
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, capecitabine, oxaliplatin in colorectal cancer (CRC), sponsored by University of California, Davis. Planned start Jun 2007; status: withdrawn.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00408772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00408772.